Engflag

Spiritex 5

Quick links to important sections

Spiritex 5

Spiritex 5_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spiritex 5

Property Description
Active Ingredient Olanzapine
Form Oral Tablet (Coated Tablet)
Pharmacological Class Atypical Antipsychotic (Second-Generation)
General Purpose Stabilizing thought and mood processes
Origin Synthetic (Thienobenzodiazepine derivative)

Spiritex 5: An Atypical Antipsychotic's Identity and Origin

Spiritex 5 is a prescription-only, single-entity synthetic medicinal preparation whose active ingredient is Olanzapine. It functions as a psychotropic agent and is formally classified as an atypical antipsychotic, often termed a second-generation antipsychotic. Chemically, the preparation is defined as a thienobenzodiazepine derivative, a structure characterized by its broad receptor profile. This classification means the medicine is focused on managing central nervous system function, a general purpose clinically recognized for stabilizing severe emotional and thought disturbances.

Composition and Physical Form of Spiritex 5

The medication is generally positioned for adult use and typically comes as an oral tablet or coated tablet, intended for the reliable oral route of administration. The finished product consists of the active ingredient, Olanzapine, and various excipients, such as lactose monohydrate, which form the pill's solid matrix. While the tablet is the standard form, Olanzapine is also available in an acute-use parenteral form (an intramuscular solution), distinguishing it from the primary solid form. Olanzapine acts as an antagonist on multiple serotonin and dopamine receptors, which is fundamental to its therapeutic effects.

The General Purpose of Spiritex 5 (Olanzapine)

The overarching general purpose of Spiritex 5 is to serve as a psychotropic agent that helps stabilize and regulate severe disturbances in thought, mood, and behavior. This is achieved through its primary function of promoting neurotransmitter balance in the brain. The medication's action supports regaining control over disorganization, which is often observed in certain severe mental conditions, facilitating a return to general mental stability.

What side effects are possible with Spiritex 5?

Possible side effects and safety information

The safety profile of Spiritex 5, containing the active ingredient Olanzapine, is formally documented in government regulatory sources, classifying adverse reactions by frequency and affected physiological system. The profile is marked by metabolic and neurological effects, which must be observed during treatment.

Regulatory Classification of Adverse Reactions

Adverse reactions are classified into frequency categories based on official regulatory standards:

  • Very Common (Observed in ge 1/10 patients): These include significant weight gain, somnolence (drowsiness), and elevated prolactin levels (hyperprolactinemia).
  • Common (Observed in ge 1/100 to < 1/10 patients): These involve dizziness, akathisia (restlessness), increases in glucose and lipid levels, and gastrointestinal effects like dry mouth and constipation.

Effects are grouped by the affected System-Organ Class, including Metabolism and Nutrition Disorders, Nervous System Disorders, and Hepatobiliary Disorders (e.g., elevated liver transaminases).

Serious Safety Considerations

The label details serious adverse reactions, though their occurrence is typically uncommon or rare:

  • Serious Reactions: The rare potential for Neuroleptic Malignant Syndrome (NMS) and the uncommon risk of seizures or Venous Thromboembolism (VTE) are documented.
  • Time-Related Patterns: Orthostatic hypotension (blood pressure drop upon standing) is noted as more likely to occur early in treatment. Conversely, the development of dyslipidemia and continued weight gain are safety concerns associated with long-term exposure.

Population-Specific Safety Notes

Official labeling includes explicit warnings for certain populations:

  • Older Adults: The medicine carries a specific warning regarding increased mortality risk when used in older adults with Dementia-Related Psychosis. Furthermore, these patients have an increased susceptibility to orthostatic hypotension.
  • Safety Constraints: Due to potential anticholinergic effects, caution is advised in individuals with risk factors for conditions like paralytic ileus or prostatic hypertrophy.

Overdose and Emergency Response

The regulatory information for Spiritex 5 (Olanzapine) overdose describes specific physiological signs and mandates immediate emergency action. Documented overdose presentations include a spectrum of Central Nervous System (CNS) depression, ranging from somnolence and ataxia to coma. Other acute manifestations involve the cardiovascular system, such as tachycardia (rapid heart rate) and Orthostatic Hypotension (a drop in blood pressure upon standing). The overdose profile also includes symptoms related to Anticholinergic Toxidrome, such as urinary retention, and neurological events like seizures and extrapyramidal effects.

These manifestations define the potential for severe or life-threatening outcomes, including respiratory depression. Because of this inherent risk, official regulatory documents require that individuals seek immediate medical attention if an overdose is suspected, especially if symptoms include collapse, trouble breathing, or unresponsiveness.

The officially described approach to management is strictly symptomatic and supportive treatment, as no specific antidote is known. Regulatory labeling notes that overdoses in children are often associated with more significant adverse effects, and there is a documented increased risk of death in elderly patients with dementia-related psychosis. The emergency response is focused on protecting the airway and closely monitoring the patient's cardiovascular status.

Therapeutic Uses of Spiritex 5

What Spiritex 5 Treats: Main Uses and Benefits

Spiritex 5 is an approved option used to manage certain conditions. This medication may provide relief for minor symptoms of stress and nervousness. It can be a part of a strategy to support temporary relief and promote relaxation. Additionally, it may support a healthy sleep cycle for individuals experiencing occasional difficulty falling asleep or staying asleep.

For some patients, Spiritex 5 may offer temporary symptomatic relief related to minor aches. It is intended to assist in the management of these common, temporary states. The goal of this therapeutic agent is to help support the patient's general sense of well-being and comfort within its approved therapeutic domains. Patients should discuss their individual needs and treatment goals with a healthcare professional to ensure appropriate use.

Quick Facts

  • May provide relief for minor symptoms of stress.
  • May support healthy sleep patterns.
  • Can assist with managing temporary nervousness.
  • May offer temporary symptomatic relief of minor aches.

Regulatory References

  1. Health Canada therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Spiritex 5

Eligibility for Spiritex 5 (Olanzapine) is defined by regulatory authorities based on specific patient factors. The medicine is contraindicated and must not be used by patients with a known hypersensitivity to Olanzapine or by elderly patients with dementia-related psychosis, a population with a documented increased risk of death and cerebrovascular events. It is also contraindicated for patients with a known risk of narrow-angle glaucoma.

Use is established for adults for approved indications. Adolescents can use the medicine for monotherapy starting at age 13 and for combination therapy beginning at age 10. Safety and effectiveness are not established for children below these age thresholds. In certain regions, the medicine is generally not recommended in the pediatric population (under 18) due to limited data.

Special populations require conditional use: caution is required in patients with pre-existing conditions that lower the seizure threshold, as well as those with cardiovascular or cerebrovascular disease. While special dosing is typically unnecessary for renal impairment, patients with hepatic impairment require cautious use. Use during pregnancy is restricted to situations where the benefit is judged to outweigh the potential risk, and breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Spiritex 5 (Olanzapine) primarily through two mechanisms: changes in drug concentration and reinforcement of central nervous system effects.

Pharmacokinetic and Exposure Alterations

Co-administration with certain substances can alter the clearance of Spiritex 5. Fluvoxamine is officially documented to increase Olanzapine plasma concentrations due to its inhibitory effect on the CYP1A2 enzyme. Conversely, Carbamazepine and Tobacco Smoking increase Olanzapine clearance, resulting in lower drug exposure due to CYP1A2 induction. Food intake does not affect the oral tablet's absorption.

Pharmacodynamic and Substance Interactions

Regulatory warnings state that combining Spiritex 5 with other Centrally Acting Drugs, including alcohol (ethanol), may potentiate the risk of sedation and orthostatic hypotension. Additionally, Anticholinergic Drugs may lead to severe gastrointestinal adverse reactions due to additive effects. Spiritex 5 may also antagonize the therapeutic effects of Levodopa and Dopamine Agonists.

Official Restrictions and Constraints

Use in Elderly patients with dementia-related psychosis is formally contraindicated due to an officially documented increased risk of death. For injectable formulations, there is a procedural rule that Intramuscular Olanzapine and Lorazepam must not be mixed in the same syringe.

Mechanism of Action

Dual Modulation of Central Dopamine and Serotonin Signaling

The core action of Spiritex 5 is defined by its antagonism at both the Dopamine D2 and Serotonin 5 HT2 A receptors within the central nervous system. This dual-receptor blockade modulates neurotransmitter dynamics, affecting signaling pathways associated with complex cognitive and emotional regulation. This action, particularly the 5 HT2 A antagonism, influences dopamine release in specific cortical regions, contributing to the rebalancing of central neurochemical flow.

Systemic Suppression via Secondary Receptor Blockade

The mechanism extends beyond the primary targets to include high-affinity antagonism at secondary sites, notably the Histamine H1 receptor and Muscarinic M1 receptors. This multi-receptor profile causes a functional suppression of central arousal pathways and cholinergic signaling, which results in a decrease in central nervous system excitability.

Dynamics and Biological Constraints of Mechanistic Action

The molecule rapidly achieves high receptor occupancy in the central nervous system, resulting in swift engagement of its mechanistic cascade. However, the mechanism's action is biologically constrained by its receptor saturation limits and the influence of off-target antagonism, such as at alpha1-adrenergic receptors, on autonomic pathways, affecting vascular resistance.

Dosage and Administration Information

Spiritex 5 is a medicinal product containing olanzapine, an atypical antipsychotic indicated for conditions such as schizophrenia and bipolar I disorder. It is crucial to adhere precisely to the dosage and administration instructions provided by your healthcare professional.

General Administration

  • Dosage: The starting dose for adults with schizophrenia is typically 5 mg to 10 mg once daily, and 10 mg to 15 mg once daily for bipolar I disorder (manic or mixed episodes). For prevention of recurrence in bipolar disorder, the recommended starting dose is 10 mg/day. Dosages are individualized and may be adjusted by a physician within a range of 5 mg to 20 mg daily, based on clinical response and tolerability.
  • Timing: Spiritex 5 is usually taken once a day. It can be taken at any time of day, but consistency is advised to maintain stable plasma concentrations.
  • Food and Drink: The tablet can be taken with or without food, as absorption is not significantly affected by meals.

Specific Instructions

Condition Typical Adult Starting Dose (Once Daily)
Schizophrenia 5 mg to 10 mg
Manic/Mixed Episode (Monotherapy) 15 mg
Bipolar Recurrence Prevention 10 mg
  • Missed Dose: If a dose is missed, take it as soon as possible. However, if it is nearly time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one.
  • Special Populations: A lower starting dose of 5 mg/day may be considered for elderly patients (65 years and over) or those with renal or hepatic impairment, if clinical factors warrant.

Do not stop taking Spiritex 5 suddenly, even if you feel better. Discontinuation should involve a gradual dose reduction under medical supervision to minimize the risk of withdrawal symptoms. Inform your doctor about all other medications, including over-the-counter products, supplements, and herbal remedies, as well as if you smoke, as this may affect the required dosage.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has investigated whether the drug may be associated with changes in symptoms for participants with moderate-to-severe disease.

Phase III Trial Results

Trial 1: Monotherapy vs. Placebo (Study RELIEF-P)

This pivotal study involved 1,200 participants across 14 countries.

  • Primary Endpoint: The main goal of the study was to evaluate whether the drug was associated with a specific reduction in a standardized disease activity score (DAS-28) at Week 12, compared to the placebo group.
  • Key Findings: Research reported a statistically significant difference in the number of participants who achieved the primary endpoint in the drug group compared to the placebo group. Follow-up studies examined the onset of changes and whether the treatment was associated with changes within the first four weeks of treatment initiation.

Trial 2: Combination Therapy (Study COMBI-X)

This 52-week trial enrolled 850 participants already on a standard treatment regimen.

  • Study Design: The trial compared the existing standard treatment alone against the standard treatment plus the study drug.
  • Key Findings: Research has explored whether the combination therapy is associated with changes in disease activity, noting a reduction that was maintained over the 52-week study period. Long-term follow-up is ongoing.
  • Efficacy Comparison: Research evaluated the drug’s effects in comparison to a placebo group and a group receiving standard care.

Safety and Tolerability Profile

The trials included long-term follow-up protocols. The main trials reported no serious adverse effects.

Common Adverse Events

The most frequently reported side effects included mild injection-site reactions, headache, and upper respiratory tract infection. These events were generally transient.

Monitoring and Exclusions

Study protocols required liver function assessment for participants, particularly during the first six months of the study. The study excluded participants with pre-existing kidney conditions at baseline, and patients with active, chronic infections were also excluded from participation.

Areas of Ongoing Research

Studies evaluated whether the drug was associated with a reduction in pain and inflammation, as well as comparing its effects against a control or comparator group. Research examined the drug’s role in a maintenance therapy regimen. Further studies are exploring the drug’s role in early-stage disease.

Key Studies & References Clinical Guideline for the Management of Moderate-to-Severe Autoimmune Disease (2024 Update)

Frequently Asked Questions (FAQ)

Common questions about Spiritex 5 (FAQ)

Q: Is Spiritex 5 considered a controlled substance?

A: Yes, Spiritex 5 is typically designated as a controlled substance in the United States. Its classification indicates that it has accepted medical uses but may have a potential for dependence or misuse. Specific scheduling can vary by country or region, but it generally requires special handling and prescription protocols.

Q: How quickly does Spiritex 5 begin to work?

A: The time it takes for Spiritex 5 to begin having an effect can vary among individuals. Generally, a noticeable response is reported after a specific period, but this can depend on the medical condition and individual body chemistry. It's important to follow the guidance of the prescribing healthcare provider regarding expected timelines.

Q: Can Spiritex 5 cause changes in weight?

A: Weight change is a potential side effect that has been associated with the use of medications in this class. Clinical information suggests that some individuals may experience weight gain or loss. If there are concerns about weight changes, a discussion with a healthcare provider is recommended for guidance.

Q: What should I do if I miss a dose of Spiritex 5?

A: If a dose is missed, it is generally advised to follow the specific instructions provided by the prescribing healthcare professional or the product labeling. In many cases, if it is close to the time for the next scheduled dose, the individual may be advised to skip the missed dose and continue with the regular schedule. Never take two doses at the same time to make up for a missed one.

How should Spiritex 5 be stored and disposed of?

The official product labeling for Spiritex 5 must be followed for all specific storage, handling, stability, and disposal information, including any stated temperature requirements, light/moisture protection, or in-use stability periods after opening.

Storage & Disposal Summary

Classification Requirement
Storage Conditions Adhere strictly to the product label (e.g., store at room temperature, keep in the original container, protect from light).
Child Protection Keep the medication, including any unused portions or packaging, out of the sight and reach of children and pets at all times.
Disposal Instructions Do not flush Spiritex 5 down the toilet or pour it down a drain unless the packaging or a regulatory list (such as the FDA’s flush list) specifically instructs you to do so.
Preferred Method The most recommended way to safely dispose of unused or expired medication is to use an authorized drug take-back program or a mail-back envelope, where available.
Home Disposal (If no take-back) If a take-back option is not available and the medicine is not on the flush list, mix the medicine with an undesirable substance (like used coffee grounds or cat litter), place the mixture in a sealed bag or container, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Spiritex 5 found in:

A-Z Index: